Bosch Group Acquires Pharmatec
In 2006, with 160 associates, Pharmatec generated sales of around €30m
Pharmatec subsidiary Schoeller-Bleckmann Medizintechnik is also part of the transaction
Approval by anti-trust authorities was granted without conditions
STUTTGART, Germany, July 9, 2007-- – The Bosch Group has
acquired Pharmatec GmbH based in Dresden, Germany, from Fresenius
ProServe GmbH. Part of this transaction is Pharmatec subsidiary
Schoeller-Bleckmann Medizintechnik Ges.m.b.H based in Ternitz,
Austria. This acquisition has been approved by the anti-trust
authorities without conditions. Pharmatec is a leading company in
pharmaceutical plant engineering. The focus is on hygienic and
sterile process technologies, in particular in the areas of pharma
and biotechnology.
In fiscal 2006, Pharmatec GmbH and its around 160 associates
generated sales of approximately €30m. "Pharmatec and
Schoeller-Bleckmann Medizintechnik are both recognized specialists
which will complement our existing product range in the pharma
packaging technology sector", said Friedbert Klefenz, chairman of
the divisional board of Packaging Technology. It was agreed to
observe confidentiality concerning the purchase price.
The Packaging Technology division undertakes development,
manufacture and marketing of Bosch process and packaging machines
and lines for the confectionery, food and luxury food sectors as
well as for the pharmaceutical industry. In 2006 the division, with
a workforce of around 3780 associates, generated global sales of
approximately €570m.
Press contact:
Christian Fronek, Tel.: 0049-(0)711-811-6131
The Bosch Group is a leading global supplier of technology and services. In the areas of automotive and industrial technology, consumer goods, and building technology, around 260,000 associates generated sales of 43.7 billion euros in fiscal 2006. The Bosch Group comprises Robert Bosch GmbH and its roughly 300 subsidiary and regional companies in over 50 countries. This worldwide development, manufacturing and sales network is the foundation for further growth. Bosch spends more than three billion euros each year on research and development, and in 2006 applied for over 3000 patents worldwide. The company was set up in Stuttgart in 1886 by Robert Bosch (1861-1942) as "Workshop for Precision Mechanics and Electrical Engineering".
The special ownership structure of Robert Bosch GmbH guarantees the
entrepreneurial freedom of the Bosch Group, making it possible for
the company to plan over the long term and to undertake significant
up-front investments in the safeguarding of its future. 92 per cent
of the share capital of Robert Bosch GmbH is held by Robert Bosch
Stiftung GmbH, a charitable foundation. The majority of voting
rights are held by Robert Bosch Industrietreuhand KG, an industrial
trust. The entrepreneurial ownership functions are carried out by
the trust. The remaining shares are held by the Bosch family and by
Robert Bosch GmbH.
More information at www.bosch.com.
[Rudolf G. Winklhofer] [ABI Europe] [27-31 Clerkenwell Close] Unit
510 [London, United Kingdom EC1R 0AT] [+44 (0)207 014 3501]
[rwinklhofer@abipr.com]
Pharma Industry News Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
